Skip to main content

Advertisement

SpringerLink
Log in

Non-IgE-Mediated Drug Hypersensitivity Reactions

  • Anaphylaxis and Drug Allergy (BT Kelly and M Castells, Section Editors)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Non-IgE-mediated drug reactions have traditionally been poorly defined and studied, though they are the most common form of hypersensitivity. Their presentations are highly variable and can range in severity from mild, cutaneous-only reactions to severe systemic disease.

Recent Findings

The most notable advance in non-IgE-mediated hypersensitivity reactions is in diagnostics. HLA alleles have traditionally been used for identifying certain patients at risk for abacavir hypersensitivity syndrome, but more recent studies have shown several other HLA alleles associated with severe cutaneous adverse reactions with various medications. This article also highlights the use of delayed intradermal testing for radiocontrast media and patch testing for delayed antibiotic reactions.

Summary

Drug reactions remain a major cause of morbidity and reason for treatment changes. Non-IgE-mediated reactions have had an increase in research interest over the past decade with an increased emphasis on better understanding the clinical presentation and underlying pathophysiology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:

    • Of importance

      •• Of major importance

      1. Wong A, Seger DL, Lai KH, Goss FR, Blumenthal KG, Zhou L. Drug hypersensitivity reactions documented in electronic health records within a large health system. J Allergy Clin Immunol Pract. 2019;7(4):1253-60.e3. https://doi.org/10.1016/j.jaip.2018.11.023 Epub 2018 Dec 1.

      2. Gomes ER, Demoly P. Aug Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5(4):309-16. https://doi.org/10.1097/01.all.0000173785.81024.33 PMID: 15985812.

      3. Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019;40(6):470-73. https://doi.org/10.2500/aap.2019.40.4274 PMID: 31690397.

      4. Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, et al. Beta-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. The Journal of Allergy and Clinical Immunology 2018; 141(1): 235–49 e8.

      5. Monroy-Arreola A, Duran-Figueroa NV, Mendez-Flores S, Dominguez-Cherit J, Watkinson J, Badillo-Corona JA, et al. Up-regulation of T-cell activation microRNAs in drug-specific CD4(+) T-cells from hypersensitive patients. Chem Res Toxicol. 2018;31(6):454–61.

        Article  CAS  PubMed  Google Scholar 

      6. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237–41.

        Article  CAS  PubMed  Google Scholar 

      7. Porebski G, Kwiecien K, Pawica M, Kwitniewski M. Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions. Front Immunol. 2018;9:3027. Study showed single nucleotide polymorphisms in the MRGPRX2 receptor may predispose patients for direct activation from multiple frequently used medications.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      8. Bircher AJ, Hofmeier KS. Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol. 2012;129(1):263–4.

        Article  PubMed  Google Scholar 

      9. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. 2014;69(4):420–37.

        Article  CAS  PubMed  Google Scholar 

      10. Patel S, John AM, Handler MZ, Schwartz RA. Fixed drug eruptions: an update, emphasizing the potentially lethal generalized bullous fixed drug eruption. Amer J Clin Derm. 2020;21:393–9.

        Article  Google Scholar 

      11. Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions: a 20-year review. Contact Dermat. 2011;65(4):195–201.

        Article  Google Scholar 

      12. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013 May;133(5):1197–204.

      13. Lehloenya RJ, Peter JG, Copascu A, Trubiano JA, Phillips EJ. Delabeling delayed drug hypersensitivity: how far can you safely go? J Allergy Clin Immunol Pract. 2020;8(9):2878-95.e6. Excellent and detailed review on testing and drug challenges for delayed hypersensitivity reactions.

        Article  PubMed  PubMed Central  Google Scholar 

      14. Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12(3):171-80.

      15. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490-97.

      16. Cianferoni A. Non–IgE-mediated anaphylaxis. Journal of allergy and clinical immunology. 2021;147(4):1123–31. https://doi.org/10.1016/j.jaci.2021.02.012.

        Article  CAS  PubMed  Google Scholar 

      17. Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges. 2012;10(12):889–97. https://doi.org/10.1111/j.1610-0387.2012.08000.x.

        Article  PubMed  PubMed Central  Google Scholar 

      18. Tasker F, Fleming H, McNeill G, Creamer D, and Walsh S. Contrast media and cutaneous reactions. Part 1. Immediate hypersensitivity reactions to contrast media and gadolinium deposition. Clin Exp Derm. 2019; 44(8): 844–60.

      19. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European society of contact dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis. 2015;73:195–221.

        Article  PubMed  Google Scholar 

      20. Zinn Z, Gayam S, Chelliah MP, Honari G, Teng J. Patch testing for nonimmediate cutaneous adverse drug reactions. J Am Acad Dermatol. 2018;78:421–3.

        Article  PubMed  Google Scholar 

      21. Barbaud A, Weinborn M, Garvey L, Testi S, Kvedariene V, Bavbek S, et al. Intradermal tests with drugs: an approach to standardization. Front Med (Lausanne). 2020;7:156.

        Article  Google Scholar 

      22. Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143:66–73.

        Article  CAS  PubMed  Google Scholar 

      23. Torres MJ, Sánchez-Sabaté E, Alvarez J, Mayorga C, Fernández J, Padial A, Cornejo-García JA, Bellón T, Blanca M. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy. 2004;59(2):219-224. https://doi.org/10.1046/j.1398-9995.2003.00308.x PMID: 14763937.

      24. Syrigou E, Zande M, Grapsa D, Syrigos K. Severe delayed skin reaction during intradermal testing with beta-lactam antibiotics. J Allergy Clin Immunol Pract. 2016;4:158–9.

        Article  PubMed  Google Scholar 

      25. Makris MP, Koulouris S, Kalogeromitros D. Nonimmediate systemic hypersensitivity reaction to beta-lactam intradermal tests. J Investig Allergol Clin Immunol. 2010;20:630–1.

        CAS  PubMed  Google Scholar 

      26. Trubiano JA, Chua KYL, Holmes NE, Douglas AP, Mouhtouris E, Goh M, et al. Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. J Allergy Clin Immunol Pract. 2020;8:1142-6.e4.

        Article  PubMed  Google Scholar 

      27. D’Amelio CM, Aramendia JM, Yuste JR, Fusco JP, Gastaminza G, Goikoetxea MJ. Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity. Ann Allergy Asthma Immunol. 2015;114:534–5.

        Article  PubMed  Google Scholar 

      28. Blanca-Lopez N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. J Asthma Allergy. 2019;12:217–33.

        Article  PubMed  PubMed Central  Google Scholar 

      29. Ahn YH, Koh YI, Kim JH, Ban GY, Lee YK, Hong GN, et al. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity. J Korean Med Sci. 2015;30:245–51.

        Article  PubMed  PubMed Central  Google Scholar 

      30. Trautmann A, Brockow K, Behle V, Stoevesandt J. Radiocontrast media hypersensitivity: skin testing differentiates allergy from nonallergic reactions and identifies a safe alternative as proven by intravenous provocation. J Allergy Clin Immunol Pract. 2019;7:2218–24.Study that has suggested a change in the approach of patients with RCM hypersensitivity by utilizing skin prick and intradermal testing more routinely.

        Article  PubMed  Google Scholar 

      31. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.

        Article  CAS  PubMed  Google Scholar 

      32. Ozkaya-Bayazit E, Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol. 2001;45(5):712-17.

      33. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLAB*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      34. Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144:183–92.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      35. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393:183–98.

        Article  PubMed  Google Scholar 

      36. Buonomo A, Nucera E, Pecora V, Rizzi A, Aruanno A, Pascolini L, et al. Crossreactivity and tolerability of cephalosporins in patients with cell-mediated allergy to penicillins. J Investig Allergol Clin Immunol. 2014;24:331–7.

        CAS  PubMed  Google Scholar 

      37. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. The very limited usefulness of skin testing with penicilloyl-polylysine and the minor determinant mixture in evaluating nonimmediate reactions to penicillins. Allergy. 2010;65:1104–7.

        CAS  PubMed  Google Scholar 

      38. Phillips E, Knowles SR, Weber EA, Blackburn D. Cephalexin tolerated despite delayed aminopenicillin reactions. Allergy. 2001;56:790.

        Article  CAS  PubMed  Google Scholar 

      39. Picard M, Robitaille G, Karam F, Daigle J-M, Bédard F, Biron É, et al. Crossreactivity to cephalosporins and carbapenems in penicillin-allergic patients: two systematic reviews and meta-analyses. J Allergy Clin Immunol Pract. 2019;7:2722-2738.e5.

        Article  PubMed  Google Scholar 

      40. Buonomo A, Nucera E, De Pasquale T, Pecora V, Lombardo C, Sabato V, et al. Tolerability of aztreonam in patients with cell-mediated allergy to betalactams. Int Arch Allergy Immunol. 2011;155:155–9.

        Article  CAS  PubMed  Google Scholar 

      41. Nakkam N, Gibson A, Mouhtouris E, Konvinse KC, Holmes N, Chua KY, Deshpande P, Li D, Ostrov DA, Trubiano J, Phillips EJ. Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. J Allergy Clin Immunol. 2020;S0091–6749(20):30687-694.

      42. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71:1527–34.

        Article  CAS  PubMed  Google Scholar 

      43. De Luca F, Losappio LM, Mirone C, Schroeder JW, Citterio A, Aversano MG, et al. Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. Clin Mol Allergy. 2017;15:16.

        Article  PubMed  PubMed Central  CAS  Google Scholar 

      44. Garcia Rodriguez R, Moreno Lozano L, Extremera Ortega A, Borja Segade J, Galindo Bonilla P, Gomez TE. Provocation tests in nonimmediate hypersensitivity reactions to beta-lactam antibiotics in children: are extended challenges needed? J Allergy Clin Immunol Pract. 2019;7:265–9.

        Article  PubMed  Google Scholar 

      45. • Van Gasse AL, Ebo DG, Chiriac AM, Hagendorens MM, Faber MA, Coenen S, et al. The limited value of prolonged drug challenges in nonimmediate amoxicillin (clavulanic acid) hypersensitivity. J Allergy Clin Immunol Pract. 2019;7:2225-9.e1. One of several studies showing that prolonged drug challenges are unlikely needed when evaluating for delayed drug reactions as single day challenges are adequate and safe.

        Article  PubMed  Google Scholar 

      46. Tonson la Tour A, Michelet M, Eigenmann PA, Caubet JC. Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1321–26.

      47. Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis. 2011;15(12):1649–57.

        Article  CAS  PubMed  Google Scholar 

      48. Lehloenya RJ, Isaacs T, Nyika T, Dhana A, Knight L, Veenstra S, et al. Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure. J Allergy Clin Immunol Prac. 2021;9(1):582-4.e1. Small but significant study showing that early use of IV steroids may reduce severity and progression of SCARs with re-exposure to culprit medication.

        Article  Google Scholar 

      49. Trautmann A, Benoit S, Goebeler M, Stoevesandt J. "Treating through" decision and follow-up in antibiotic therapy-associated exanthemas. J Allergy Clin Immunol Pract. 2017;5(6):1650–56.

      50. Khodoun MV, Kucuk ZY, Strait RT, Krishnamurthy D, Janek K, Clay CD, Morris SC, Finkelman FD. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis. J Allergy Clin Immunol. 2013;132(6):1375-87.

      51. Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116–23.

      52. Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007;(2):CD005646.

      53. Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, Faggion I, Landonio S, Quirino T. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Biomed Pharmacother. 2000;54(1):45–9.

      54. Straatmann A, Bahia F, Pedral-Sampaio D, Brites C. A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides. Braz J Infect Dis. 2002;6(6):276-80.

      55. Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, Wesley M, Sarracco T, Cooper EC, Dratter V, Smith JJ, Frost KR; American Foundation for AIDS Research (amfAR) Community-Based Clinical Trials Network. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184(8):992–7.

      56. Krantz, Matthew S, Stone, Cosby A, Abreo, Andrew, Phillips, Elizabeth J. Oral challenge with trimethoprim-sulfamethoxazole in patients with “sulfa” antibiotic allergy. The Journal of Allergy and Clinical Immunology in Practice (Cambridge, MA). 2020;8(2):757–60.e4. Important study that showed single or two dose challenges to sulfonamide antibiotics is safe and effective in patients with nonsevere delayed cutaneous reactions.

      57. Pérez-Rodríguez E, Martínez-Tadeo JA, Pérez-Rodríguez N, Hernández-Santana G, Callero-Viera A, Rodríguez-Plata E, García-Robaina JC. Outcome of 490 Desensitizations to chemotherapy drugs with a rapid one-solution protocol. J Allergy Clin Immunol Pract. 2018;6(5):1621–27.e6.

      58. Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015;3(2):175–85; quiz 186.

      59. Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol. 2017;8:1472. Published 2017 Nov 8. https://doi.org/10.3389/fimmu.2017.01472.

      60. Berges-Gimeno MP, Carpio-Escalona LV, Longo-Muñoz F, Bernal-Rubio L, Lopez-Gonzalez P, Gehlhaar P, Pachon V, Ferreiro-Monteagudo R, Madrigal-Burgaleta R, Alvarez-Cuesta E. Does rapid drug desensitization to chemotherapy affect survival outcomes?. J Investig Allergol Clin Immunol. 2020;30(4):254–63. https://doi.org/10.18176/jiaci.0425. (Epub 2019 Jun 12 PMID: 31188129).

        Article  CAS  PubMed  Google Scholar 

      61. Shaker MS, Wallace DV, Golden DBK, Oppenheimer J et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-23.

      62. Macy EM. Current epidemiology and management of radiocontrast-associated acute- and delayed-onset hypersensitivity: a review of the literature. Perm J. 2018;22:17–072.

        PubMed  Google Scholar 

      63. Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137:1674–80.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      64. Munoz-Cano R, Picado C, Valero A, Bartra J. Mechanisms of anaphylaxis beyond IgE. J Investig Allergol Clin Immunol. 2016;26:73–82.

        Article  CAS  PubMed  Google Scholar 

      65. Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147(4):1123-31. https://doi.org/10.1016/j.jaci.2021.02.012. PMID: 33832694.

      66. Sekula P, Dunant A, Mockenhaupk M, Naldi L, Bouwes-Bavinck JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–204.

        Article  CAS  PubMed  Google Scholar 

      67. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.

        Article  PubMed  Google Scholar 

      68. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. NEJM. 1993;328(23):1670–4.

        Article  CAS  PubMed  Google Scholar 

      69. Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017;37(2):397-12. https://doi.org/10.1016/j.iac.2017.01.012. Epub 2017 Mar 2 PMID: 28366484.

      70. Joshi SR, Khan DA. Anaphylaxis induced by biologics. Curr Treat Options Allergy. 2019;6:125–41.

        Article  Google Scholar 

      71. Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2(1):40–5. https://doi.org/10.1016/j.jaip.2013.08.011.

        Article  PubMed  Google Scholar 

      72. Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol. 2017;8(8):1472. https://doi.org/10.3389/fimmu.2017.01472.PMID:29163536;PMCID:PMC5676049.

      73. Sánchez-Borges, Mario et al. Controversies in drug allergy: radiographic contrast media. J Allergy and Clin Immunol Pract. 2019;7(1):61–5.

      74. Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, et al. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018;8:11628.

        Article  PubMed  PubMed Central  CAS  Google Scholar 

      75. Yuan F, Zhang C, Sun M, Wu D, Cheng L, Pan B, Li T, Che D. MRGPRX2 mediates immediate-type pseudo-allergic reactions induced by iodine-containing iohexol. Biomed Pharmacother. 2021 May;137:111323.

      76. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, Renaudin JM, Beaudouin E, Laudy JS, Moneret-Vautrin DA. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol. 2005;115(1):179-85.

      Download references

      Author information

      Authors and Affiliations

      1. Section of Allergy and Immunology, Oregon Health and Science University, Portland, OR, USA

        Shyam R. Joshi

      2. Division of Allergy and Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA

        David A. Khan

      Authors
      1. Shyam R. Joshi
        View author publications

        You can also search for this author in PubMed Google Scholar

      2. David A. Khan
        View author publications

        You can also search for this author in PubMed Google Scholar

      Corresponding author

      Correspondence to David A. Khan.

      Ethics declarations

      Conflict of Interest

      The authors declare no conflicts of interest relevant to this manuscript.

      Human and Animal Rights and Informed Consent

      This article does not contain any studies with human or animal subjects performed by any of the authors.

      Additional information

      Publisher's Note

      Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

      This article is part of the Topical Collection on Anaphylaxis and Drug Allergy

      Rights and permissions

      Reprints and permissions

      About this article

      Check for updates. Verify currency and authenticity via CrossMark

      Cite this article

      Joshi, S.R., Khan, D.A. Non-IgE-Mediated Drug Hypersensitivity Reactions. Curr Allergy Asthma Rep 21, 41 (2021). https://doi.org/10.1007/s11882-021-01018-7

      Download citation

      • Accepted:

      • Published:

      • DOI: https://doi.org/10.1007/s11882-021-01018-7

      Keywords

      Search

      Navigation